Articles

In a new study, undergoing a colonoscopy was associated with an overall 70% reduction of advanced colorectal cancer diagnoses. Read More ›

Oncology nurse navigators work in a variety of settings, including hospitals, outpatient clinics, oncology groups, and accountable care organizations (ACOs). Their pa­tients have every conceivable type of cancer and a variety of treatment plans. Nurse navigators often follow patients from diagnosis through the entire spectrum of care. Their task has been to find the resources to help patients from diagnosis through care and recovery or relapse. Read More ›

Researchers have discovered that consuming a daily dose of omega-3 fish oils enhances skin immunity to sunlight. Read More ›

The National Lung Screening Trial found that LDCT screening reduces lung cancer deaths by about 20% compared with chest x-ray. Read More ›

Novel cancer care technology now allows doctors to treat prostate cancer from within the body. Read More ›

The FDA recently approved a new therapy for patients with HER2-positive, metastatic breast cancer who had previously received treatment with trastuzumab and taxanes. Read More ›

The majority of women who undergo breast cancer operations involving axillary lymph node removal experience anxiety related to the possible development of lymphedema. Read More ›

Updated findings from the pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial found robust activity and sustained benefit for the investigational tyrosine kinase inhibitor ponatinib in heavily pretreated patients with accelerated or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). Read More ›

Bevacizumab (Avastin; Genentech) received FDA approval on January 23, 2013, for use in combination with fluoropyrimidine-irinotecan–based or fluoropyrimidine-oxaliplatin–based chemotherapy for treating patients with metastatic colorectal cancer (mCRC) with disease that has progressed on a regimen containing first-line bevacizumab. Read More ›

The US Food and Drug Administration (FDA) approved doxorubicin hydrochloride liposome injection (Sun Pharma Global FZE) for the treatment of patients with ovarian cancer with disease progression after platinum-based chemotherapy and for the treatment of AIDS-related sarcoma in patients after failure of systemic chemotherapy or intolerance to that therapy. Read More ›